As big pharmaceutical companies vie to enter the medical cannabis space and establish a foothold with overpriced and inaccessible cannabis based drugs…
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
“In June 2018, the FDA approved a cannabidiol (CBD) prescription medication for the first time. Called Epidiolex, it is approved specifically to treat seizures in two rare, severe forms of child-onset epilepsy in patients who are 2 and older.
This approval precipitated the removal of Epidiloex specifically from the Controlled Substances Act, allowing its sale and transport, with a doctor’s prescription, in every state in the US.
Now GW Pharma is trying to bring a second cannabis formulation to the United States, with Phase 3 trials now beginning for Sativex for for the treatment of MS spasticity. The cannabis based drug is also being studied by Kings College London for use by people living with dementia, specifically Alzheimer’s Disease.
Sativex known Nabiximols in the US, is a 1:1 formulation of CBD and THC:
“Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids THC and CBD and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols and triglycerides, according to company data. The product is administered as an oral spray.”
Since 2011, Farmacann has established itself as the leader in research and development of cannabis therapeutics based on evidence of efficacy in real world environments in Northern California Residential Care Facilities and in the homes of patients throughout the area.
And as California’s legal and regulatory environment has changed, so has Farmacann, by developing products and packaging that always meet or exceed the manufacturing, testing and regulatory requirements of the State of California, Medical Professionals and Licensed Care Facilities.
While the rest of the country waits for Big Pharma to enter the medical cannabis space, Farmacann is delivering relief to 7 counties in the Bay Area with the same ratio and established efficacy:
Ratio CBD:THC: 1:1
Dosage: 5mg CBD and 5mg THC (each capsule)
Packaging: Pill Cards of 30 capsules, each that contain a total of 300mg of combined cannabinoids.
Ideal for: Patients seeking a balance between physical comfort and mental relaxation.
And with a monthly subscription at $81, inclusive of state and local taxes and delivery, this is cannabis medicine that is accessible now in Northern California, and soon the entire state and beyond.
Farmacann – Providing seniors & medical professionals with a technology platform that simplifies access to effective & affordable alternative cannabis choices